Literature DB >> 25436807

Successful desensitization of two patients with ALK-positive lung cancer and hypersensitivity to crizotinib.

Mark M Awad1, Timothy P Lax, Benjamin R Slawski, Alice T Shaw.   

Abstract

The tyrosine kinase inhibitor crizotinib is an effective therapy for patients with cancers harboring rearrangements of the anaplastic lymphoma kinase (ALK) gene. Here, we describe two patients with advanced ALK-positive lung cancer who developed hypersensitivity to crizotinib, requiring temporary discontinuation of the drug. Both patients were treated with a rapid oral desensitization protocol allowing them to resume crizotinib without further signs or symptoms of hypersensitivity.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25436807     DOI： 10.1097/JTO.0000000000000350

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


  8 in total

1.  Successful oral desensitization with crizotinib after crizotinib-induced hepatitis in an anaplastic lymphoma kinase-rearranged non-small-cell lung cancer patient: A case report.

Authors:  Yuto Yasuda; Yasuyo Nishikawa; Yuichi Sakamori; Makoto Terao; Kentaro Hashimoto; Tomoko Funazo; Takashi Nomizo; Takahiro Tsuji; Hironori Yoshida; Hiroki Nagai; Hiroaki Ozasa; Toyohiro Hirai; Young Hak Kim
Journal:  Mol Clin Oncol       Date:  2017-06-29

2.  Hypersensitivity in ALK-positive lung cancers exposed to ALK inhibitors: a case of successful switch to an alternative ALK inhibitor and systematic review of the literature.

Authors:  Lei Deng; Janaki Sharma; Elizabeth Ravera; Balazs Halmos; Haiying Cheng
Journal:  Lung Cancer (Auckl)       Date:  2018-09-06

3.  Successful Desensitization with Crizotinib after Crizotinib-induced Liver Injury in ROS1-rearranged Lung Adenocarcinoma.

Authors:  Takayo Ota; Noriyuki Masuda; Kaoru Matsui; Takao Yamada; Noriko Tanaka; Shunsuke Fujimoto; Masahiro Fukuoka
Journal:  Intern Med       Date:  2019-06-07       Impact factor: 1.271

4.  [Recommendations from Experts in the Management of Adverse Reactions 
to ALK Inhibitors (2021 Version)].

Authors:  Ke Wang; Juan Li; Jianguo Sun; Li Li; Xi Zhang; Jianyong Zhang; Min Yu; Xianwei Ye; Ming Zhang; Yu Zhang; Wenxiu Yao; Meijuan Huang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2021-10-21

5.  Successful oral desensitization with osimertinib following osimertinib-induced fever and hepatotoxicity: a case report.

Authors:  Ryosuke Hirabayashi; Daichi Fujimoto; Yukari Satsuma; Masaki Hirabatake; Keisuke Tomii
Journal:  Invest New Drugs       Date:  2018-05-02       Impact factor: 3.850

6.  Treatment of severe rash caused by crizotinib with both traditional Chinese medicine and Western medicine: Two case reports and literature review.

Authors:  Shu-Yue Zheng; Wen Shen; Yan-Mei Peng; Hui-Juan Cui; Hua Duan; Yu-Qin Qiu; Qiang Li; Jing-Yi Zhang; Chen-Yao Sun; Xu Zhang
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817

7.  Successful Desensitization Treatment with Osimertinib after the Development of Osimertinib-induced Urticaria in a Patient Undergoing Treatment for Non-small Cell Lung Cancer Harboring the EGFR T790M Mutation.

Authors:  Go Makimoto; Tatsuya Nishi; Keita Kawakado; Tomoka Nishimura; Tomoki Tamura; Kenichiro Kudo; Shoichi Kuyama
Journal:  Intern Med       Date:  2020-05-26       Impact factor: 1.271

8.  Usefulness of Rapid Desensitization Therapy for Severe Rash Caused by Molecularly Targeted Drugs Used in the Treatment of Non-small-cell Lung Cancer.

Authors:  Maki Nagase; Nobuharu Ohshima; Masahiro Kawashima; Masahiro Ohgiya; Miki Ikeda; Yoshiteru Morio; Atsuhisa Tamura
Journal:  Intern Med       Date:  2020-08-12       Impact factor: 1.271
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.